Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

Ebina, Yasuhiko; Watari, Hidemichi; Kaneuchi, Masanori et al.

European journal of nuclear medicine and molecular imaging, 2014, 41(3), 446-451

Permalink : https://hdl.handle.net/2115/58233

このアイテムのアクセス数:1,052件（2026-08-14 15:57 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
Eur J Nucl Med Mol Imaging_41(3)_446-451 pdf 646 KB 906

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/58233
タイトル
Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer
著者
Ebina, Yasuhiko ; Watari, Hidemichi ; Kaneuchi, Masanori ; Takeda, Mahito ; Hosaka, Masayoshi ; Kudo, Masataka ; Yamada, Hideto ; Sakuragi, Noriaki
著者名
Ebina, Yasuhiko
e-Rad_Researcher
10344508
著者名
Watari, Hidemichi
著者名
Kaneuchi, Masanori
著者名
Takeda, Mahito
著者名
Hosaka, Masayoshi
著者名
Kudo, Masataka
著者名
Yamada, Hideto
e-Rad_Researcher
70153963
著者名
Sakuragi, Noriaki
言語
英語
キーワード
Ovarian cancer
Recurrence
Cytoreduction
FDG PET
発行日
2014-03
出版者
Springer
収録物名
European journal of nuclear medicine and molecular imaging
巻(号)
41(3)
ページ
446-451
抄録
Purpose To investigate the impact of PET and PET/CT scanning on decision-making in management planning and to identify the optimal setting for selecting candidates for surgery in suspicious recurrent ovarian cancer. Methods A retrospective chart review was performed in patients with possible recurrent ovarian cancer after primary optimal cytoreduction and taxane/carboplatin chemotherapy who had undergone FDG PET or FDG PET/CT scans from July 2002 to August 2008 to help make treatment decisions. The analysis included 44 patients who had undergone a total of 89 PET scans. The positive PET scans were classified as follows. (1) localized (one or two localized sites of FDG uptake), (2) multiple (three or more sites of FDG uptake), (3) diffuse (extensive low-grade activity outlining serosal and peritoneal surfaces). Results Of the 89 PET scans, 52 (58.4 %) led to a change in management plan. The total number of patients in whom cytoreductive surgery was selected as the treatment of choice increased from 12 to 35. Miliary disseminated disease, which was not detected by PET scan, was found in 22.2 % of those receiving surgery. Miliary disseminated disease was detected in 6 of the 12 patients with recurrent disease whose treatment-free interval (TFI) was <12 months, whereas none of those with a TFI of >= 12 months had such disease (P = 0.0031). Conclusion PET or PET/CT is useful for selecting candidates for cytoreductive surgery among patients with recurrent ovarian cancer. To avoid surgical attempts in those with miliary dissemination, patients with a TFI of >= 12 months are the best candidates for cytoreductive surgery.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
The final publication is available at Springer via http://dx.doi.org/10.1007/s00259-013-2610-9
PISSN
1619-7070
EISSN
1619-7089
NCID
AA1161516X
関連情報
PMID
24221243
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s00259-013-2610-9